Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Dow
Moodys
AstraZeneca
Medtronic

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR CALQUENCE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Calquence

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02972840 ↗ A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Recruiting Acerta Pharma BV Phase 3 2017-04-05 This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.
NCT03516617 ↗ Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 2018-09-10 This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
NCT03516617 ↗ Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting Mayo Clinic Phase 2 2018-09-10 This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
NCT03580928 ↗ Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Recruiting Acerta Pharma Phase 2 2018-07-30 This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: - Acalabrutinib - Venetoclax - Obinutuzmab
NCT03580928 ↗ Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Recruiting Acerta Pharma, LLC Phase 2 2018-07-30 This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs involved in this study are: - Acalabrutinib - Venetoclax - Obinutuzmab
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Calquence

Condition Name

Condition Name for Calquence
Intervention Trials
Chronic Lymphocytic Leukemia 10
Mantle Cell Lymphoma 9
Small Lymphocytic Lymphoma 6
Grade 3a Follicular Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Calquence
Intervention Trials
Lymphoma 26
Leukemia, Lymphocytic, Chronic, B-Cell 14
Lymphoma, Mantle-Cell 13
Leukemia, Lymphoid 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Calquence

Trials by Country

Trials by Country for Calquence
Location Trials
United States 118
Japan 7
Canada 5
Australia 3
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Calquence
Location Trials
Texas 10
Massachusetts 7
Washington 6
New York 6
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Calquence

Clinical Trial Phase

Clinical Trial Phase for Calquence
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 31
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Calquence
Clinical Trial Phase Trials
Recruiting 28
Not yet recruiting 12
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Calquence

Sponsor Name

Sponsor Name for Calquence
Sponsor Trials
AstraZeneca 18
National Cancer Institute (NCI) 15
M.D. Anderson Cancer Center 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Calquence
Sponsor Trials
Other 45
Industry 27
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Mallinckrodt
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.